Life Science Investing Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
Life Science Investing Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference
Life Science Investing Adicet Bio Announces First Systemic Sclerosis Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
life science investing Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference
life science investing Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
life science investing Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference
life science investing Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy 28th Annual Meeting
life science investing Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference
life science investing Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress
life science investing Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer 2025 Spring Scientific Meeting
Equity Metals Reports First Assays from No. 3 North 2025 Expansion Drilling, Including 540 g/t AgEq over 3.5m, Silver Queen Property, BC
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference
